247rxpill.in

Warning LetterOpen

247rxpill.in United StatesIssued Aug 31, 2021Center for Drug Evaluation and Research | CDER

View Letter

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy.

Violations2

Issue DateAug 31, 2021

Product TypeDrugs

StatusOpen

Letter Details

Firm: 247rxpill.in
Location: 247rxpill.in United States
FEI Number: N/A
Country: United States
Issue Date: August 31, 2021
Issuing Office: Center for Drug Evaluation and Research | CDER
Product Type: Drugs
Status: Open

Summary

247rxpill.in was cited for introducing unapproved and misbranded opioid and benzodiazepine drugs into interstate commerce through its website, violating sections 301(a), 301(d), and 505(a) of the Federal Food, Drug, and Cosmetic Act. The FDA emphasized that these controlled substance violations posed significant public health risks given the ongoing opioid epidemic and the potential for benzodiazepine abuse, particularly when combined with other drugs. The agency noted that unapproved drugs lack safety and effectiveness assurances and may be contaminated or otherwise unsafe.

247rxpill.in FDA Warning Letter, August 31, 2021